B. Riley initiated coverage on shares of MacroGenics (NASDAQ:MGNX – Free Report) in a research note published on Friday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $25.00 price objective on the biopharmaceutical company’s stock. A number of other brokerages also recently issued reports on MGNX. TD Cowen raised shares of […]
JMP Securities restated their market outperform rating on shares of MacroGenics (NASDAQ:MGNX – Free Report) in a research report report published on Thursday, Benzinga reports. A number of other research firms have also recently commented on MGNX. BTIG Research boosted their price target on shares of MacroGenics from $12.00 to $24.00 and gave the stock […]
GSA Capital Partners LLP increased its position in shares of MacroGenics, Inc. (NASDAQ:MGNX – Free Report) by 74.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 225,918 shares of the biopharmaceutical company’s stock after buying an additional 96,760 shares during the […]
MacroGenics, Inc. (NASDAQ:MGNX – Get Free Report) has been assigned a consensus rating of “Buy” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have updated their coverage on the stock […]
MacroGenics (NASDAQ:MGNX – Free Report) had its target price raised by JMP Securities from $10.00 to $16.00 in a report released on Wednesday, Benzinga reports. They currently have a market outperform rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently issued reports on the company. StockNews.com cut MacroGenics from a buy […]